HS-10504 clinical trials
HS-10504 is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Jiangsu Hansoh Pharmaceutical Co., Ltd. The most-studied condition is Advanced or Metastatic NSCLC.
Patient leaflets for HS-10504
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of HS-10504
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC
NCT07754123 · ClinicalTrials.gov ↗ · Advanced or Metastatic NSCLC
|
Phase 3 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd | China |
|
A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
NCT06461156 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic NSCLC
|
Phase 1 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with HS-10504
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Jiangsu Hansoh Pharmaceutical Co., Ltd | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about HS-10504 trials
How many clinical trials are testing HS-10504?
2 current trials in our China register name HS-10504 as a drug or biological intervention, as of the registry sync on 3 November 2026. Completed and withdrawn studies are not counted.
Are HS-10504 trials recruiting patients?
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors HS-10504 clinical trials?
The lead sponsor is Jiangsu Hansoh Pharmaceutical Co., Ltd. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how HS-10504 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how HS-10504 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists HS-10504 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 3 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.